Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Benjamin N. Bekele"'
Autor:
Maher N. Youne, Orhan G. Yigitbasi, Steven I. Sherman, Mahitosh Mandal, Bradley A. Schiff, FChristopher C. Holsinger, Benjamin N. Bekele, Sai Ching Yeung, Adel K. El-Naggar, Ge Zhou, Samar A. Jasser, Jeffrey N. Myers, Dao Doan, Andrea B. McMurphy, Seungwon Kim
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 25(15)
Autor:
Elihu H. Estey, Wanlong Ma, Benjamin N. Bekele, Hagop M. Kantarjian, Zhong J. Zhang, Maher Albitar, Jorge E. Cortes, Amber C. Donahue, Zeev Estrov, Francis J. Giles, Susan O'Brien, Xi Zhang, Michael J. Keating
Publikováno v:
Clinical Cancer Research. 15:3820-3826
Purpose: Cytogenetic abnormalities are currently the most important predictors of response and clinical outcome for patients with acute myeloid leukemia (AML) or advanced-stage myelodysplastic syndrome (MDS). Because clinical outcomes vary markedly w
Autor:
Benjamin N. Bekele, A. Ferrajoli, William G. Wierda, Iman Jilani, Chongjuan Wei, Zeev Estrov, M. Albitar, Susan O'Brien, Zhong J. Zhang, Hagop M. Kantarjian, Francis J. Giles, M. Keating
Publikováno v:
International Journal of Laboratory Hematology. 31:97-105
Syndecan-1 (sCD138) is a transmembrane heparan sulfate-bearing proteoglycan expressed in epithelial cells as well as hematopoietic cells that demonstrate plasmacytoid differentiation. Higher levels of sCD138 correlate with poor outcome in myeloma. We
Autor:
Amanda Hartman, Benjamin N. Bekele, Rajagopal Ramesh, Cynthia D. Branch, Satoshi Inoue, L. Clifton Stephens, Corazan D. Bucana, Sunil Chada
Publikováno v:
Molecular Therapy. 15:287-294
Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has shown antitumor activity by inhibiting tumor angiogenesis in preclinical and clinical studies. However, bevacizumab monotherapy does not induce comple
Autor:
Jane M. Geraci, Linda S. Elting, Catherine D. Cooksley, Benjamin N. Bekele, Scott B. Cantor, Elenir B. C. Avritscher, Kenneth V. I. Rolston
Publikováno v:
Cancer. 109:2357-2364
BACKGROUND. Despite recommendations to immunize all patients at an increased risk of influenza complications, the vaccine utilization among high-risk nonelderly adults remains low and its cost-effectiveness is unclear. In the current study, the autho
Autor:
Zeev Estrov, Xian Zhou, Yihua Qiu, Benjamin N. Bekele, C. Ellen Jackson, Michael Andreeff, Steven M. Kornblau, David Harris, Jenny Straka Cade
Publikováno v:
Cell Cycle. 5:2769-2777
We hypothesized that studying protein expression in cells surviving in vitro chemotherapy ("survivor cells", SV), could provide more important insight into the biology of drug-resistant AML cells than analysis of the bulk population of leukemic cells
Autor:
Paul Mathew, Danai D. Daliani, Benjamin N. Bekele, Xian Zhou, Christopher J. Logothetis, I. Chen, Lance C. Pagliaro, Pauline Dieringer
Publikováno v:
Clinical Genitourinary Cancer. 5:144-149
Background This is a phase I/II trial of thalidomide with estramustine and paclitaxel in men with androgen-independent prostate cancer (AIPC) who underwent previous chemotherapy. Patients and Methods Men with progressive AIPC were treated with oral t
Autor:
Abha Khanna, Tanweer M. Zaidi, Ruiyun Li, Huijun Wang, Benjamin N. Bekele, Ruth L. Katz, Nancy P. Caraway, Dennis A. Johnston, Ricardo Fernandez, Hua Zhong Zhang, Feng Jiang
Publikováno v:
Clinical Cancer Research. 11:5417-5424
Purpose: The present study was conducted to determine clinical relevance of surfactant protein A (SP-A) genetic aberrations in early-stage non–small cell lung cancer (NSCLC). Experimental Design: To determine whether SP-A aberrations are lung cance
Autor:
Mahitosh Mandal, Samar A. Jasser, Adel K. El-Naggar, Bradley A. Schiff, Gordon B. Mills, Benjamin N. Bekele, Yasemin D. Yazici, Jeffrey N. Myers, Orhan G. Yigitbasi, Maher N. Younes, Seungwon Kim
Publikováno v:
Molecular Cancer Therapeutics. 4:1146-1156
We investigated integrin-linked kinase (ILK), a focal adhesion serine-threonine protein kinase, as a new molecular target for treating anaplastic thyroid cancer. ILK mediates cell growth and survival signals and is overexpressed in a number of cancer
Autor:
Benjamin N. Bekele, Isaiah J. Fidler, Mahitosh Mandal, Yasemin D. Yazici, Samar A. Jasser, Sun Jin Kim, Valerie S. Hawthorne, Young Wook Park, Corazon D. Bucana, Maher N. Younes, Jeffrey N. Myers, Orhan G. Yigitbasi
Publikováno v:
Cancer Research. 65:4716-4727
Patients suffering from bone metastases of follicular thyroid carcinoma (FTC) have a poor prognosis because of the lack of effective treatment strategies. The overexpression of epidermal growth factor receptor (EGFR) associated with increased vascula